A 72-year-old woman with type 2 diabetes and hypertension is admitted on day 3 of COVID-19 with fever, cough, and SpO₂ 92% on room air. Chest X-ray shows unilateral right lower lobe consolidation. She is started on supplemental oxygen and dexamethasone. On day 5 of admission, her fever persists, SpO₂ drops to 89% despite 4 L/min oxygen, and she develops purulent sputum with elevated procalcitonin (2.8 ng/mL). What is the most appropriate next step?

Explanation

## Clinical Context This patient initially presented with **moderate COVID-19** but is now showing signs of **bacterial superinfection** on day 5 of hospitalization: ### Red Flags for Secondary Bacterial Infection **Key Point:** Bacterial superinfection in COVID-19 occurs in 10–15% of hospitalized patients, typically after day 4–5 of illness, and is associated with worse outcomes. | Finding | Significance | |---------|-------------| | **Purulent sputum** | Suggests bacterial colonization/infection | | **Procalcitonin >0.5 ng/mL** | Bacterial infection likely; >2.0 suggests moderate-to-severe bacterial infection | | **Fever persistence/recurrence** | Initial improvement followed by fever spike suggests superinfection | | **Unilateral consolidation** | May indicate bacterial pneumonia (lobar pattern) vs. viral pneumonia (bilateral/diffuse) | | **Clinical deterioration** | Declining SpO₂ despite appropriate oxygen therapy | ## Diagnostic and Management Algorithm ```mermaid flowchart TD A[COVID-19 + clinical deterioration on day 5]:::outcome --> B{Signs of bacterial superinfection?}:::decision B -->|Purulent sputum + high procalcitonin + fever persistence| C[Bacterial superinfection likely]:::outcome C --> D[Blood cultures × 2]:::action D --> E[Sputum/endotracheal culture if intubated]:::action E --> F[Chest imaging: CXR or CT if diagnosis unclear]:::action F --> G[Start empiric broad-spectrum antibiotics]:::action G --> H[Ceftriaxone + azithromycin OR Piperacillin-tazobactam]:::action H --> I[De-escalate based on culture + sensitivity]:::action ``` ## Rationale for Antibiotic Therapy **High-Yield:** In hospitalized COVID-19 patients with signs of bacterial superinfection: 1. **Obtain cultures BEFORE antibiotics** — blood cultures (×2), sputum/BAL culture if feasible 2. **Start empiric antibiotics** — cover common respiratory pathogens: - **Streptococcus pneumoniae** - **Haemophilus influenzae** - **Staphylococcus aureus** (including MRSA in high-risk settings) - **Gram-negative rods** (Klebsiella, Pseudomonas if risk factors present) 3. **Recommended empiric regimens:** - **Ceftriaxone 1–2 g IV 12-hourly + Azithromycin 500 mg IV daily** (if no severe renal impairment) - **Piperacillin-tazobactam 4.5 g IV 6-hourly** (broader spectrum; preferred if Pseudomonas risk) - **Add vancomycin** if MRSA risk or severe sepsis 4. **De-escalate** once culture sensitivities available (typically 48–72 hours) **Clinical Pearl:** Do NOT delay antibiotics while awaiting culture results in a septic patient. The "golden hour" principle applies — early antibiotics reduce mortality in bacterial sepsis. ## Why This Answer Is Correct The constellation of **purulent sputum, elevated procalcitonin, fever persistence, and clinical deterioration** on day 5 of hospitalization strongly suggests **bacterial superinfection**. The next step is: 1. **Obtain cultures** (blood, sputum) to guide targeted therapy 2. **Initiate empiric broad-spectrum antibiotics** immediately (do not wait for culture results) 3. **Continue supportive care** (oxygen, dexamethasone) This approach balances diagnostic precision with clinical urgency.